Topic Highlight
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2013; 19(45): 8192-8202
Published online Dec 7, 2013. doi: 10.3748/wjg.v19.i45.8192
Table 1 Inhibitors targeting interleukin-8 in cancer progression
InhibitorsMechanismsRef.
ResveratrolReduces ROS, inhibits MAPK, AP-1 and NF-κB[82,83]
AnthocyaninReduces ROS, inhibits MAPK, AP-1 and NF-κB[84-86]
ApigeninIncreases the IκBα and thus inhibits NF-κB[88,89]
RK-I-123Reduces ROS and inhibits AP-1 and NF-κB[91]
DA-6034Dissociates IKK/HSP90 complex and inhibits NF-κB[92,93]
RebamipidePrevents PLD expression via NF-κB[94,95]
Gefitinib [Iressa™]Inhibits EGFR[98,99]
L. bulgaricusInhibits TLR4[101]
L. acidophilusDissociates IKK/Hsp90 complex and inhibits NF-κB[65,103]
NRF peptideDisrupts interaction of NRF and NF-κB[105]
miR-146Negatively regulates IL-8[110,111]
miR-155Inhibits MyD88 via NF-κB[112,115]
G31PSynthetic derivative of IL-8[117]
SCH-527123CXCR2 inhibitor[118]